

Index

a

- Abbreviated New Drug Application (ANDA) 675
- Abelcet® 182, 185, 408, 417, 700
- Abraxane® 4, 5, 33, 46, 55, 90, 192, 216, 234, 247, 409, 410, 501, 681, 702, 703
- Abraxne™ 82
- absolute neutrophil count (ANC) 480, 481, 484
- ACCURIN® 33, 723, 731
- acetylcholinesterase (AChE) 652
- Achilles' heel 615
- acidic environment 52, 283, 456
- active pharmaceutical ingredients (APIs) 8, 18, 20, 159, 192–195, 197, 198, 201, 203, 205, 206, 208, 209, 211, 212, 298, 301, 323, 367, 505, 633, 636, 640, 642, 685
 - agglomeration 197
 - milling processes 196
 - nanoparticles 203
- acute cardiovascular events 603
- acute EAE-induced mouse
 - accumulation of MPS in the liver and brain 622
- acute inflammation 549, 603
- acute respiratory distress syndrome (ARDS) 638
- AD. *see* Alzheimer's disease (AD)
- ADAGEN® 704
- ADCETRIS® 704
- ADCs. *see* antibody drug conjugates (ADCs)
- additive packing parameter (APP) 618, 649, 651
- adeno-associated virus (AAV) 7, 8, 48
- adenosine deaminase deficiency 704
- adenoviruses 7, 8, 48
- adjuvant-induced arthritis (AIA) rat model 620, 623
- adjuvants 6, 177, 180, 274, 416, 583, 637, 638, 641, 642
- aerolization 25
- AFM. *see* atomic force microscopy (AFM)
- Afrezza® 641
- age-related macular degeneration (AMD) 635, 637, 641
- agglomerates 18, 162, 332, 333, 335, 350, 431, 502
- aggregation behavior 29
- aging population 697
- AgNPs. *see* silver nanoparticles (AgNPs)
- A375 human melanoma xenografts 474
- AIDS-related Kaposi's sarcoma 483, 487
- air–blood barrier 24
- albumin 4, 5, 29, 33, 46, 47, 90, 189, 190, 247, 409, 410, 549, 550, 703, 731
 - based nanoparticles 4, 47
- alginates 33, 111, 191
- alkermes 194, 212, 213, 302, 303
- allergic conjunctivitis 640
- allergic diseases 603
- alopecia 3, 701
- alumina 34, 197
- alumina oxide 307
- aluminum hydroxide 6, 637
- aluminum particles 5, 6
- aluminum phthalocyanine disulfonate 282
- Alveofact® 633
- Alzheimer's disease (AD) 18, 43, 649–656
 - cholinergic neurotransmitter activity, role of 653
 - diagnosis 650–652
 - amyloid plaques detection 650–651
 - biomarkers detection 651–652
 - therapy 653–656
 - current therapies 653–654
 - latest therapeutic directions 654–655
 - nanomedicine 655–656
- ambisome 32, 182, 185, 189, 233, 303, 416, 417, 507, 609, 699, 700
- AmBisome® 32, 609, 699

- AMD. *see* age-related macular degeneration (AMD)
- amorphization 209
- ADME (Absorption, distribution, metabolism, and excretion) 19, 207, 386, 389–391, 394, 575, 670, 686, 708, 710, 712, 726, 730, 736
- American Society for Cell Biology 673
- American Society for Testing and Materials (ASTM) 680
- American Statistical Association (ASA) 674
- amikacin dry liposomal formulation 633
- aminosilane-coated iron oxide NPs 34
- amiodarone 119
- ammonium sulfate 186, 187, 612, 701
- amphipathic weak acids
- principles and mechanism 614
- amphiphilic block copolymers 113
- Amphocil® 182, 185, 700
- Amphotec® 182, 185, 408, 417, 681, 700
- amphotericin B 119, 185, 206, 233, 303, 408, 416, 417, 507, 634, 699, 700
- broad-spectrum antifungal drug, role as 699
 - dose-limiting toxicities 699
 - – infusion-related reactions 699
 - – nephrotoxicity 699
- amyloid beta peptide 649
- amyloid precursor protein (APP) 618, 649, 651
- analgesics 26
- analytical ultracentrifugation (AUC) 141
- anaphylactoid reaction rate 514
- ANDA. *see* Abbreviated New Drug Application (ANDA)
- anemia 34, 504, 511, 512, 549
- iron oxide nanoparticles for, treatment 504
 - nonexhaustive list of iron nanoparticles for, treatment 512
- anesthetics 121
- angiogenesis 93, 603, 637
- animal models 136, 275, 374, 490, 491, 524, 562, 566, 575, 618, 623, 636, 654, 673, 737, 739
- anisotropic etching 361
- annular mill 307, 308
- anodic bonding 363
- antibodies 5, 7, 18, 30, 33, 43, 50, 51, 71, 72, 84, 92, 243, 420, 435, 563, 637, 664, 676, 704, 705, 737
- antigen reactions 366
- antibody drug conjugates (ADCs) 4, 241, 243, 664, 704
- antibody manufacturers 674
- antibody performance 674
- anticancer agents 45, 470, 471, 474
- anticancer drug 4, 239, 277, 427, 447, 456, 606, 735
- design 606
- anticonvulsants 26
- antidepressants 26
- antiepidermal growth factor receptor (EGFR) antibodies 84, 448, 449
- antigen-binding sites 5
- antigens, tumor-associated 418
- anti-Her2 antibodies 448
- anti-HER2-targeted liposomal doxorubicin 473
- anti-inflammatory drugs 23, 604, 607, 618
- antineoplastics 120
- antisense oligonucleotide 697, 726
- antisense RNA–RISC complex 92
- antisolvent precipitation 204, 205
- API. *see* active pharmaceutical ingredient (API)
- apigenin 653
- apolipoprotein E 29, 656
- APP. *see* amyloid precursor protein (APP)
- aptamers 5, 18, 30, 50, 90, 91, 276, 473, 637, 656, 664
- ARDS. *see* acute respiratory distress syndrome (ARDS)
- Arikace® 633
- ASA. *see* American Statistical Association (ASA)
- assay cascade 136
- assay-duping molecules 674
- asthma 603, 607, 635
- ASTM. *see* American Society for Testing and Materials (ASTM)
- atherosclerosis 18, 603, 729
- atomic force microscopy (AFM) 139, 140, 571, 709
- atomization 191, 205, 210, 591
- atom transfer radical polymerization (ATRP) 259, 260
- ATRP. *see* atom transfer radical polymerization (ATRP)
- AUC. *see* analytical ultracentrifugation (AUC)
- Au-chitosan conjugates 447
- AuNPs. *see* gold nanoparticles (AuNPs)
- autofluorescence 537–539
- autoimmune disease 111, 603, 604, 607
- automatic metering with controlled powder dosing funnel on a laboratory device 346
- auxiliary emulsifiers 179

b

- BA. *see* bolaamphiphiles (BA)
- Baeyer–Villiger oxidation 256
- ballistic metaphors 526
- Bangham manufacturing technique, scaling up 309
- Bangham method used for API As' liposomes manufacturing, schematic 310
- battery-operated fog generator, checking unhindered airflow 347
- BBB. *see* blood-brain barrier (BBB)
- B cells 4, 7, 91, 471, 603, 604, 607
- bead milling technology 297, 319, 320
 - scaling up of 319
- beneficiaries 37
- beta-methasone hemisuccinate (BMS) 620
- bevacizumab 122, 489, 583, 584
- big pharma 670, 674, 683, 727
- bioavailability 3, 8, 17, 19, 47, 203, 237, 445, 586, 633, 636, 666, 721
- biocompatibility 3, 10, 33, 49, 109, 363, 366, 444, 539, 686
 - nanoparticles for medical application 446, 455
- biocompatible materials 374
- biocompatible nanopolymers 502
- biodegradability 3, 32, 35, 108, 109, 259, 272, 283, 285, 454, 456, 574, 633
- biodegradable polymers 249
 - classification 249
 - naturally occurring 249
 - synthetic 250
 - for nanomedicines 249
- biodegradation 108, 164
- biodistribution 4, 34, 36, 44, 162, 284, 428, 502, 544, 546, 588, 590, 619, 686, 711, 714
 - chromium doped persistent luminescence nanoparticles 546
- biofilms 29, 284, 366
- bioinformatics 87
- biological barriers, overcoming 22
- biological fluid 28, 29, 146, 379, 391, 572, 610, 618, 738
- biological process 66
- biological surfaces 17
- biomarkers 81, 83, 87, 95, 444, 553, 651, 652, 688, 693, 697, 707
- bio-microelectromechanical systems (BioMEMS) 357
- bio-nano interface 76
 - forces, dynamics, and other processes at 71
 - future of 76, 77
- bionanomedicine 167
- bionanoscale interactions 66
- bionanoscience 63, 75, 76
 - future of 76, 77
- biopharmaceutics classification system 35, 714 (bis(2- (succinimidooxycarbonyloxy) ethyl) sulfone) (BSOCOES) 121
- block copolymeric nanoparticles 717
- block copolymer micelles
 - nonexhaustive list, in clinical trials 516
- block copolymers 33, 234
- blood–air barrier 24
- blood-brain barrier (BBB) 25, 27, 29, 32, 35, 373, 375, 476, 477, 620, 623, 649–651, 655, 656
- blood cancer 51
- blood pool agents (BPAs) 549, 550
 - diagnostic 549
 - intravascular contrast agents 549
 - reversibility rate 550
 - size 549
- B-lymphoma cells *in vivo*, 453
- body mass index (BMI) 487
- body surface area (BSA) 487
- bolaamphiphiles (BA) 115
- bonding techniques 363
 - anodic bonding 363
 - bonding with intermediate layers 363
 - with intermediate layers 363
 - plasma-activated bonding 363
 - silicon direct bonding (SDB) 363, 364
 - solid–liquid interdiffusion bonding (SLID) 364
 - thermal bonding 363
- bottom-up processes 204, 297
 - solvent evaporation methods 638
 - solvent injection 638
- bottom-up technology 296
- bovine serum albumin (BSA) 122, 487
- brain tumors 5, 26, 34, 54, 472, 475–477
 - age 483–486
 - body habitus 487
 - CMA/PK/PD, effect of MPS 480–483
 - drug–drug interactions 488, 489
 - gender 486–487
 - liver tumors, presence of 487–488
 - particle dose 480
 - particle shape 478
 - particle size 477, 478
 - prior treatment 489, 490
 - surface charge 479, 480
 - surface modification 478–479
 - translational challenges 490, 491

- branched polymers 234, 715
- breast cancer, intracranial model 476
- breast cancer model 473
- brentuximab vedotin 4
- Brownian diffusion 428
- Brownian relaxation 568
- brush configuration 432
- BSA. *see* bovine serum albumin (BSA)
- BSOCOES. *see* (bis(2-(succinimidooxycarbonyloxy) ethyl)sulfone) (BSOCOES)
- bulk chemical composition 143
- bystander cells 417, 737
- C**
- cadmium 284, 350, 537
 - selenium nanoparticle 537
- Caelyx® 32, 182, 184, 186, 234, 303, 506, 700
- CAGR (current annual growth rate) 35, 724
- calcium phosphate (CaP) 209, 274, 283, 583, 717
- Camptosa® 702
- camptothecin (CPT) 241
- cancer 3, 4, 21, 47, 53, 81, 87, 95, 275, 381, 430, 456, 476, 535, 570, 603, 607, 703, 729
- cancer cell lines 448
- cancer stem cells (CSCs) 489, 736
- cancer therapy, oral administration for 456
- caraway oils 256
- carbohydrates 5, 189, 249, 280, 473, 513
- carbon-based materials 48
- carbon nanomaterials 34, 564
 - carbon nanotubes 564–565
 - nanographene 565
- carbon nanotubes (CNTs) 106, 333, 342, 344, 350, 427, 450, 539, 564–565, 665
 - ROS induction, via mitochondrial damage 427
- carcinoembryonic antigen (CEA) 418
- cardiotoxicity 3, 32, 407, 409, 427, 428, 506, 701
- cardiovascular diseases 18, 43, 553, 607, 724
- cardiovascular inflammation 549
- carrier-mediated agents (CMAs) 469–471, 473, 480, 486, 491
 - delivery in tumor 472–475
 - effect of MPS 480–483
 - pharmacokinetic dispositions of 482
 - pharmacokinetics 470
 - S-CKD602, 480
 - small-molecule (SM) counterparts 469
 - uptake 471
- carrier molecules 446, 447
- carvone 256, 257
 - hydrogenation 256
- cathepsin 91, 603
- cationic dendrimers 427, 432
- cationic lipids 48
 - DOTAP 49, 181
- CattleMaster Gold® 633
- cavitation 303
 - bubbles 305
- CD30, 4, 704
- cell adhesion molecules 607
- cell-derived membrane vesicles 457
- cell disruption 303, 304
- cell-specific drug delivery systems 413
- cellular and non-cellular barriers, of lung 24
- cellular energy 65
- cellular interactions 44
- cellular internalization 51
 - of nanoparticles 44
- cellulose 33, 109, 146, 195, 207, 211, 215, 434
- central nervous system (CNS) 26, 27, 36, 388, 475, 476, 636
- ceramics 34, 203, 351
- cerebrospinal fluid (CSF) 25–27, 651, 652, 655
- cetyltrimethylammonium bromide 110
- CFD. *see* computational fluid dynamics (CFD)
- chaotrope 240
- chemical composition 63
- chemistry, manufacturing, and control (CMC) 10, 738
- chemokine 7, 482, 491, 623
- chemotherapeutic concentrations 82
- chimeric antigen receptors (CARs) 85–86
- chip system, structure and design 375
- chitosans 25, 33, 111, 118, 120, 122, 189, 191, 241, 249, 277, 388, 447, 448, 455, 456, 641
 - coated PLGA carrier 25
 - PLGA NPs 25
- cholesterol 3, 49, 90, 115, 118, 181, 182, 185–187, 582, 610, 612, 617, 637, 639, 699, 700, 702
- cholinesterase inhibitors 653
- chronic inflammation 603
 - characteristics of 603
 - damages 604
 - morbidity 604
 - pathologies 604
 - rheumatoid arthritis 604
 - vs. acute inflammation 603–604
- chronic lymphocytic leukemia (CLL) 85
- circulating monocytes 471
- cisplatin 277
- CKD-602 yielded 488

- plasma concentration *versus* time profile of 482
- clearance rate, reduced 54
- CLINAM. *see* European Foundation for Clinical Nanomedicine (CLINAM)
- clinical patch test 431
- CMC. *see* chemistry, manufacturing and controls (CMC); critical micellar concentration (CMC)
- CNT-induced oxidative stress 427
- CNT PEGylation 452
- CNTs. *see* carbon nanotubes (CNTs)
- coating materials 333
- colloidal drug carriers 638
- colloidal drug delivery systems 633, 638, 681
- colloidal lipid emulsions 176
 - adjuvant emulsion MF59, preparation 180
 - composition 176
 - intravenous fat emulsions, preparation process 177
- colorectal cancer (CRC) 84, 87, 702
- combination technology (CT) 206
 - scanning 448
- combination therapy
 - challenges 698
 - nanocarrier, role of 698
- commercial instruments 63
- commercialization 10, 663, 667, 668, 671, 678–680, 700, 706, 708, 710, 716, 724
 - nanomedicines 10, 55, 136, 139, 147, 232, 261, 396, 499–504, 514–517, 526, 682, 699, 706, 714, 722, 725, 728–731, 733, 734, 740
- comminution processes 193
 - high-pressure homogenization 202
 - stirred media milling 194
- comminution step 297
- comminution technology 297
- companies in nanomedicines 733
- companion diagnostic 536
- complex cellular interrogation process 66
- composite nanomaterials 334
- computational approaches, for predicting nanotoxicology 384–386
- computational fluid dynamics (CFD) 201
- computational models 380, 381, 383–385, 396
- computer simulation 380, 381
- condensation methods 296
- confined impinging jet mixer 717
- confocal laser scanning microscopy images 454
- continuous flow microreactors process 729
- contract research organization (CRO) 739
- contrast-enhanced ultrasound 542
- contrast imaging modalities 54
- controlled micromixing 717
- controlled radical polymerization (CRP) 259
 - atom transfer radical polymerization (ATRP) 260
 - reversible addition fragmentation chain transfer (RAFT) polymerization 260
- controlling drug release 20, 21
- conventional dosage 10, 193
- conventional stabilizer system 195
- Copaxone® 32, 619, 681
- copolymers 236
 - formulation into micelles 236
 - formulation into nanoparticles 236
 - formulation into vesicles 236
- coproduction 521
- core 586
 - shell nanoparticles 162
- corona 28, 29, 67, 68, 141, 146, 285, 546, 586
- cortisol 607, 608, 613, 615
- cortisol palmitate 615
- cortisone 607
- Corynebacterium diphtheriae*, 419
- CPT. *see* camptothecin (CPT)
- cranial nerve 636
- Cremophor® 5, 33, 110, 116, 247, 248, 409, 703
- Cremophor A6, 116
- Cremophor EL® 33, 110, 409
- critical micellar concentration (CMC) 236, 737
- critical path initiative 673
- critical quality attributes (CQA)
 - principles 517
- CRO. *see* contract research organization (CRO)
- cross-linked polystyrene beads 307
- cross-linkers 111, 121, 192, 260
- crowd sourced analysis 673
- CRP. *see* controlled radical polymerization (CRP)
- cryosurgery (CS) 573, 574
 - application of extreme cold 573
 - in localized diseases 573
 - treatment of solid tumors 573
- crystal growth 297
- crystalline suspensions 306
- crystallization 8, 31, 112, 167, 204, 206, 357, 369, 588
- CSCs. *see* cancer stem cells (CSCs)
- CSF. *see* cerebrospinal fluid (CSF)
- CT. *see* combination technology (CT)
- CTAB-AuNPs 447

culture of promise 522
 curcumin 588, 650, 653, 654, 656
 current density 363
 current good manufacturing practices
 (cGMPs) 323
 current marketed nanomedicines 699–704
 – ABRIXANE® 703–704
 – amphotericin B liposomal products
 699–700
 – antibody drug conjugates (ADCs) 4, 241,
 243, 664, 704
 – Doxil® 700–701
 – Genexol-PM 703
 – liposomal products in oncology 702
 – pegylated proteins 703–704
 Cushing's syndrome 607
 cyclodextrins 656
 cystic fibrosis 603
 cytokines secretion 7
 – steroid loaded liposomal treatment, effect
 of 623
 cytotoxic oncology DNA intercalating
 drugs 434

d

daunorubicin 90, 408, 434, 508, 509, 702
 DC-derived exosomes 457
 degradation kinetics 68
 delivery systems, design of 44
 DEM. *see* discrete element method (DEM)
 dendrimers 3, 546, 585, 716
 – branched macromolecules 585
 – encapsulation capacity 585
 – molecular weight distribution 585
 dendritic cell (DC) 25, 416, 457, 471, 483, 502
 – function 483
 – material offering space for accommodating
 guest molecules in 334
 dendritic polymers 585
 dendrons 585
 Depocyt® 702
 DepotFoam® technology 187, 702
 depth lithography 360
 design functional entities 66
 developability 715
 dextrane-stabilized iron oxide
 nanoparticles 633
 dextran polymers 543
 dextran sulfate 120
 diabetes 7, 12, 18, 34, 89, 453, 497, 515, 549,
 603, 729
 – type-1, 603
 – type 2, 89

diabetic retinopathy 635, 641
 diagnostic/theranostic nanodrugs 49, 53
 DIC. *see* disseminated intravascular
 coagulation (DIC)
 dietary polyphenols 654
 differential centrifugal sedimentation (DCS) 72
 – to measure immunogold labeling 72
 differential scanning calorimetry (DSC) 609
 diffusion 21, 91, 109, 117, 119, 138, 271, 357,
 392, 610, 698
 diffusion-controlled release 21
 digestive system 167, 579
 – gastrointestinal absorption 579
 – mucus 579
 dimyristoyl phosphatidylcholine (DMPC) 182,
 185, 616, 700
 dimyristoylphosphatidylglycerol (DMPG) 182,
 185, 700
 dioleoyloxypropyltrimethylammonium
 chloride (DOTAP) 49, 181
 dipalmitoylphosphatidylcholine 53, 115
 direct injection method, development and
 scaling up of 311
 discoidal polymeric nanoconstructs
 (DPAs) 472
 discrete element method (DEM) 201
 disease-causing agents 3
 diseases involving inflammation
 – steroid loaded liposomes, treatment with
 – historical perspective 615–618
 disks mill 307
 – design 307
 dispersion 305
 disseminated intravascular coagulation
 (DIC) 432
 Disso Cubes technology 306
 DissoCube® technology 9
 dissolution 8, 17, 30, 161, 206, 207, 211, 283,
 714
 distearoyl phosphatidylglycerol (DSPG) 182,
 185, 699
 (3,3x00301;-dithiobis(sulfosuccinimidyl
 propionate)) (DTSSP) 121
 DLS. *see* dynamic light scattering (DLS)
 DMPC. *see* dimyristoyl phosphatidylcholine
 (DMPC)
 DMPG. *see* dimyristoylphosphatidylglycerol
 (DMPG)
 DMPK. *see* drug metabolism and
 pharmacokinetics
 DNA immunotherapy-based technology
 platform 731
 DNA methylation 87

- docetaxel-loaded PRINT nanoparticles 480
- docetaxel, pharmacokinetics of 481
- docosahexaenoic acid 653
- donepezil 653, 655
- DOTAP. *see*
 - dioleoyloxypropyltrimethylammonium chloride (DOTAP)
- downsizing 183, 675
- DOX. *see* Doxorubicin (DOX)
- Doxil® 3, 32, 46, 409, 609, 737
- doxil liposomal NP constructs 454
- DOXIL™ 82
- Doxil treatment 3, 52, 186, 233, 487–489, 581, 701, 702, 735, 737
- doxorubicin (DOX) 3, 45, 46, 54, 90, 110, 120, 186, 257, 277, 409, 434, 449, 473, 476, 485, 506, 516, 621, 699, 700, 702, 721, 725, 738
 - enhanced permeation and retention (EPR) of 409
 - PEGylated liposomes 54
 - sulfate crystals 612, 701
- 3D printing technology 364, 365
- drug
 - area under the time-*versus*-concentration curve (AUC) 606
 - clearance (Cl) 606
 - plasma distribution 605
 - volume of distribution 605
- drug approvals 677, 727
 - by FDA's, ten-year historic comparison 677
- drug-associated toxicity 45, 52
- drug delivery 5, 8, 18, 20, 23, 25, 34, 48, 49, 103, 108, 123, 160, 181, 233, 260, 282, 306, 403, 405, 407, 418, 475, 535, 579, 609, 638, 655, 667, 724, 738
 - to central nervous system 25
 - effectiveness of 404
 - emphasis of 406
 - nanocarriers 103
 - – gold nanoparticles 103
 - – lipid particles 103
 - – liposomes 103
 - – micelles 103
 - – quantum dots 103
 - – silica nanoparticles 103
 - – silver nanoparticles 103
 - objectives 408
 - progression 698
 - systems 45
 - value of applying nanotechnology 409
- drug development 93, 216, 372, 373, 389, 396, 404, 411–413, 666, 676, 687, 688, 728
 - pharmaceutical properties 413
 - predictive parameters 412
 - preferential localization of drugs 412
 - role of, targeted nanoformulations 412
- drug discovery 8, 20, 357, 374, 381, 405, 411, 667, 674, 698, 705
 - engine 674
- drug disposition 18, 421
- drug-drug interactions 380, 488, 491, 707
- drug efflux pumps 489
- drug encapsulation 105, 112, 115–118, 633
- drug formulation 27, 135, 195, 357, 403, 406, 421, 483, 523, 680
- druggable space 698
- drug loading 3, 34, 112, 116, 118, 137, 282, 480, 703, 715, 717, 738, 739
 - liposomes, cytotoxic effect of 54
- drug metabolism and pharmacokinetics (DMPK) 405
- drug nanocrystals 106
 - classification methods 107
 - synthesis methods 107
- drug nanoparticles 106, 176, 192, 193, 201, 207, 212, 581
 - drying methods 207
 - marketed products 212
 - process chains to solid formulations 192
 - size-determining processes 193
- drug particle size-determining processes 193
 - bottom-up processes 204
 - comminution processes 193
 - hybrid/combinative methods 205
- drug penicillin 63
- drug plasma distribution 605
- drug:polymer ratio 122
- drug product definition 309
- drug release 116, 147, 722
- drug safety profile 555
- drug screening 674
- drug stability 49
- drug targeting 105, 403–405, 413, 605, 636
 - assessment 404
 - characteristics of 406
 - definition 404, 406
 - delivery 403
 - details of 404
 - discovery 676
 - drug formulation 403
 - goal of 403
 - in lipid nanoparticles 420–421
 - new drug development 404
 - particle size for 414, 415
 - sites of action 413–414
 - target distribution 410

- tissue and cell targets 404
- drug toxicity 373, 428
- nanoparticle distribution, role of 428
- dry etching 360, 361
- dry eye syndrome 633
- DSC. *see* differential scanning calorimetry (DSC)
- DTSSP. *see* (3,3x00301;-dithiobis (sulfosuccinimidyl propionate)) (DTSSP)
- dust-free decanting 347
- dynamic light scattering (DLS) 138, 139, 142, 146, 709, 710
- e**
- EAE mice model 618
 - accumulation of MPS originating 622
 - steroidal liposomes, treatment with 619
- Ebola 7
- EDA. *see* ethylenediamine (EDA)
- EE. *see* encapsulation efficiencies (EE)
- egg phosphatidylcholine (EPC) 186
- Elan technology 307
- electrical discharge machining (EDM) 365
- electrical properties 332
- electrochemical biosensors 651, 652
- electrolytic cell 363
- electromechanical stability 113
- electronic microscopy 738
- electroplating 360, 363, 366
- electroporation 25, 725, 731
 - delivery system 731
- electrostatic stabilization 176
- EMA. *see* European Medicine Agency (EMA)
- Emend® 31, 107, 215
- emtansine 4, 704
- emulsification–reverse saltingout 190
- emulsification–solvent evaporation 190
- emulsification–solvent extraction 190
- emulsions 110–113, 122, 176–178, 297, 303, 431, 637
 - solvent diffusion technique 109
 - stabilization of 303
- Enabling NANomedicine TRANSLation project (ENATRANS) 728
- ENATRANS. *see* Enabling NANomedicine TRANSLation project (ENATRANS)
- encapsulated drug 46, 712
 - physicochemical properties 547
- encapsulating systems 233
- encapsulation efficiencies (EE) 110
- endogenous trafficking 66
- Endorem® 549, 633, 634
- endosomes 4, 30, 52, 568
- endotoxin 137, 145, 146, 430, 434, 711, 720, 738
 - mediated inflammation 434
- energy transfer coefficient 201
- engineered nanomaterials
 - common toxicities 429
- engine machining 429
- enhanced permeability and retention (EPR)
 - effect 3, 4, 23, 30, 32, 45, 51, 90, 232, 409, 455, 472, 473, 478, 491, 563, 605, 699, 701, 736, 737
 - effect 3, 4, 23, 30, 32, 45, 51, 90, 232, 409, 455, 472, 473, 478, 491, 563, 605, 699, 701, 736, 737
- environment, health, and safety (EHS) 34
- enzyme-dependent release 22
- Epaxal® 637
- EPC. *see* egg phosphatidylcholine (EPC)
- epidermal growth factor receptor (EGFR) 4, 83, 84, 448, 704
 - mutations 449
- epigallocatechin gallate 653
- epigenome 81, 86
- epithelial–endothelial barriers 23
- epithelial ovarian cancer (EOC) 483
- EPR. *see* enhanced permeability and retention effect (EPR)
- Equilis® 634, 638
- Equip® 634, 638
- equipment design requirements 325
 - equipment cleaning in place (CIP) 326
 - equipment drying in place 326
 - equipment sterilization in place (SIP) 326
 - facility requirements 327
- erosion-controlled release 21
- erythropoietin (EPO) 453
- Escherichia coli*, 611
- ESNAM. *see* European Society for Nanomedicine (ESNAM)
- ESS. *see* European Spallation Source (ESS)
- etch techniques 360–362
 - anisotropic 361
 - dry etch 362
 - isotropic 361
 - wet chemical 362
- ethanol amount optimization 311
- ethanol and vesicle size change during evaporation, removal of
 - using agitated thin film evaporator 315
- ethical considerations 521

- ethical, legal, and social implications (ELSI) 521
- ethylenediamine (EDA) 241, 361
- EU-NCL. *see* European Nanomedicine Characterisation Laboratory (EU-NCL)
- European Commission
 - concretize observance of nanoscale proportions 333
 - defined nanomaterials as 18
 - define nanotechnology 331
- The European Commission in 2011 502
- European Foundation for Clinical Nanomedicine (CLINAM) 504, 724
- European Medicine Agency (EMA) 48, 256, 426, 498, 499, 636, 720
 - benefit/risk balance evaluation 500
 - iron-based preparations 511
 - and nanomedicines 499
 - novel mechanism of action 500
 - requirements 511
 - scientific committees 498
 - scientific secretariat 498
- European Nanomedicine Characterisation Laboratory (EU-NCL) 136, 396, 708, 722
- European Nanomedicine Technology Platform 708
- European Society for Nanomedicine (ESNAM) 724
- European Society for Translational Medicine 667
- European Spallation Source (ESS) 170
- European Technology Platform on Nanomedicine (ETPN) 504
- evaporator 325
- experimental cerebral malaria (ECM) 620
- Exubera® 641, 642
- ex vivo* murine melanoma (B16) 458
- eye drops 636

- f**
- Fab2 fragments 5
- fast renal accumulation 547
- FDA. *see* Food and Drug Administration (FDA)
- Federal Drugs Administration (FDA) 720
- Feraheme® 34
- Feridex® 50, 54
 - nanoparticles 54
- FFF. *see* field flow fractionation (FFF)
- fibrous nanocarriers 430
 - nanobelts 430
 - nanoribbons 430
- fibrous nanomaterials, 337
 - pulmonary toxicity 430
- field flow fractionation (FFF) 138, 140
- first-generation nanocarriers 95, 715
 - linear polymer conjugates 715
 - liposomes 715
- Fischer esterification 251
- flakes 333
- flocculation 176, 297
- Fluenz® 636
- fluidized bed granulation 211, 297
- fluorescent dyes
 - encapsulation of 538
 - indocyanin green (ICG) 538
- Food and Drug Administration (FDA) 256, 453, 499, 564, 666
- freedom-to-operate 678, 685
- free drug concentration 713
- free-radical polymerization 259
- freeze-dried cake as function of residual ethanol content 313
- freeze-drying 206, 301
- from laboratory to clinic
 - overcoming valley of death 666–673
- front loading 714, 722
 - approach 722
- 5-FU, delivery to tumors 475
- fullerenes 105, 333, 350

- g**
- gadoleptic acid (Bracco SpA) 549
- gadofosveset 549
- gadolinium 55, 168, 279, 543, 549
 - based chelates 543
 - chelates 544
- gadomelitol (Guerbet) 549
- galantamine 653, 655
- gastrointestinal mucosa 23
- gastrointestinal (GI) tract 240, 456
- GCs. *see* glucocorticosteroids (GCs)
- gelatin 33, 111, 191
- gel exclusion chromatography 738
- gel filtration 118
- Gendicine 48
- gene delivery systems 48, 446, 450
- generic development methodology 320
- gene therapy 7, 12, 19, 44, 47, 48, 55
 - clinical trials 48
- genetic disease risks 89
- genetic engineering 666
- Genexol-PM® 33, 47, 237
- Genexol's block copolymer 455
- glass 159, 209, 359, 364
- glaucoma treatment 641

- Gleason Score 570
- global translational science
 - organizations 687–693
- glucocorticoid receptor (GR) 607
- glucocorticoids 618
- glucocorticosteroids (GCs) therapy 604, 607–609
 - acetate prodrugs 607
 - anti-inflammatory immunosuppressive effects 607
 - in autoimmune diseases 607
 - GC–GR complex, physiological effect 607
 - physiological effect 608
 - physiological mechanisms 607
 - in sclerosis 608
 - in Sjögren's syndrome 608
 - strategies for, formulating liposomal GCs 612–615
- glutathione level 52
- Glybera 48
- glycerol 176, 178, 214
- glycolide 254
- glycoprotein 5, 248, 418
- GMP. *see* good manufacturing practice (GMP)
- gold nanoparticles (Au NPs) 3, 43, 103, 138, 231, 272, 446, 561, 652
 - advantages of 561, 562
 - based sensors 652
 - chitosan 447
 - conjugates 448
 - colloidal synthetic methods for 561
 - composite 279
 - mesoporous silica NPs (MSNs) 279
 - conjugated (covalent and noncovalent) 276, 277
 - facile conjugation 561
 - lipids, hybrid nanosystems composed of 277
 - polymer/polyelectrolyte coating 277
 - scattering properties 562
 - shapes 562
 - and optical properties 272–276
 - solubility 561
 - therapeutics 448
- gold nuggets 674
- good manufacturing practice (GMP) 11, 145, 217, 739
- governmental transparency 665
- GR. *see* glucocorticoid receptor (GR)
- granulation 210, 297, 301
- graphene 332, 333
 - nanostructures 450
- graphene oxide 665
- GR-bound proteins 607
 - HSP70, 607
 - HSP90, 607
 - p23, 607
 - Src 607
- h**
- hafnium oxide nanoparticles 571
 - atomic number 571
 - clinical development 572
 - efficacy of 571
 - physical mode of action 571
 - therapeutic effectiveness of, radiotherapy 571
- hairy cell leukemia (HCL) 419
- hand-foot syndrome (HFS) 482, 486, 701
- handheld measuring device 342
- HAVpur[®] 637, 642
- HCL. *see* hairy cell leukemia
- HeLa cells 282, 447, 567
- hemagglutinin 416, 637
- heparin 23, 587
- heparosan polymer 243
- hepatitis A vaccine (Epaxal) 416, 642
- hepatocellular carcinoma (HCC) 53, 87, 241
- HER2. *see* human epidermal growth factor receptor-2 (HER2)
- high aspect ratio nanomaterials (HARN) 332
- high-content analysis 86
- high-intensity focused ultrasound (HIFU) 53
- high-performance liquid chromatography (HPLC) 719
- high-pressure homogenization (HPH) 8, 108, 176, 185, 202, 295, 302, 306, 319, 321
 - scaling up of 319
- high-pressure homogenizers 180, 193, 297, 639
 - piston gap technology 305
- high-pressure nanonization systems 367–369
- high-quality magnetic nanoparticles
 - chemical methods of, synthesis 568
- high-throughput screening 374, 385, 421, 676
- HIP. *see* hydrophobic ion-pairing (HIP)
- HIV 7, 9, 405, 417, 497
- hollow mesoporous silica NPs (HSNs) 282
- homogeneous supersaturation conditions 717
- homogenization (s) 112, 180, 186, 205, 305, 320
- homogenization pressure (Pa) 180, 304, 320
- homopolymerization 250
- horseradish peroxidase (HRP) 652
- HPH. *see* high-pressure homogenization (HPH)
- HPLC. *see* high-performance liquid chromatography (HPLC)

- HPMA. *see* N-(2-hydroxypropyl) methacrylamide (HPMA)
- HRP. *see* horseradish peroxidase (HRP)
- HSPC. *see* hydrogenated soy phosphatidylcholine (HSPC)
- human cervical carcinoma (HeLa) 455
- human clinical trials 674, 739
- human epidermal growth factor receptor-2 (HER2) 4, 704
- targeted liposomes 51
- Human Genome Project 521
- “human-on-a-chip” systems 374
- Human Proteome Organization 87
- human suicide genes 85
- hybrid/combinative methods 205
- antisolvent precipitation 205
 - freeze-drying 206
 - spray-drying 206
- hydrocortisone 210, 612
- hydrodynamic traps 359
- hydrogenated soy phosphatidylcholine (HSPC) 185, 700
- hydrophilic drugs 119, 611
- hydrophilic fraction 114
- hydrophilic molecules 26, 45, 119, 637
- hydrophilic polymers 28, 111, 118
- hydrophilic stabilizer 296
- hydrophobic drug 33, 90, 117, 119, 233, 611
- hydrophobic ibuprofen 119
- hydrophobic interactions 5
- hydrophobic ion-pairing (HIP) 119
- hydrophobic molecules 25
- hydrophobic polymers 109
- hydroxyapatite (HA) NPs 283
- hydroxyethyl starch 243
- hyperglycosylation 247
- hyperthermia procedure 5, 34, 52, 53, 569
- apoptotic 570
 - for treatment of, glioblastoma 570
- i*
- ICH. *see* International Committee of Harmonization (ICH)
- IDD-P®. *see* insoluble drug delivery particles process (IDD-P®)
- illumina sequencing 87
- image-guided nanodrugs 50
- imaging modalities, 54, 549, 553, 736
- summary of current nanoparticles in 551
- immune response 8, 25, 36, 415, 457, 603, 633
- immune-stimulating complexes (ISCOMs) 641
- immune system 7, 48, 95, 389, 432
- immunoactive cells 603, 609
- immunocompetent dendritic cells 502
- immunogenicity 48, 115, 232, 435
- immunoglobulin G (IgG) 414
- immunoglobulins 618
- immunoliposomes 115, 421
- immunological barriers 28
- immunotherapy 654–655
- active 654–655
 - passive 654–655
- immunotoxins 419
- indium 537
- indium-111 54
- induced pluripotent stem cells (iPSCs) 654
- inflammasome activation 434
- inflammation. *see also* glucocorticosteroid therapy
- brief historical perspective 615–618
 - endotoxins, role of 430
 - nanoparticles-based drug delivery systems (DDS) for, treatment 605–607
 - – proinflammatory molecules 606
 - – targeting macrophages 606
 - pathological states 603
 - phases of 603
 - therapeutic strategies for 604–605
 - use of liposomes loaded with steroids for treatment 615–618
 - *in vivo* experimental animal models 618
- inflammation involving diseases 603–604
- inflammation treatment
- common therapeutic strategies 604–605
 - nanoparticles-based drug delivery systems (DDS) 605–607
 - nanotechnology, use of 606
 - – targeting macrophages 606
 - – targeting proinflammatory molecules 606
- inflammatory and autoimmune disorders 432
- inflammatory bowel diseases 23, 607
- inflammatory lung disorders 429
- inflammatory mediators 603
- inflammatory process phases 603
- acute inflammation 603
 - chronic inflammation 603
 - immune response 603
- inflammatory transcription factors 607
- Inflexal® 642, 681
- influenza A virus 637

- inhaled insulin 641
 - injectable nanoemulsions 725
 - innovation gap 666
 - inorganic materials 135, 271, 568
 - inorganic nanoparticles 33, 139, 538
 - for pharmaceutical applications 273, 274
 - inorganic nanostructures 104, 106
 - inorganic NPs 34, 271, 444
 - based delivery system 271
 - inorganic oxides 379
 - in silico* tools, for predicting efficacy, toxicity, and 380
 - insoluble drug delivery particles pocess (IDD-P®) 203
 - instruction and training 351
 - insulin 23, 249, 591, 641
 - intact organic nanoparticles 144
 - integrated personal omics profiling (iPOP) 88
 - interaction chamber 180, 304, 319
 - interdisciplinary contribution 44
 - interesting effects 63
 - interfacial tension force scales 358
 - interleukin 12 (IL-12) 49
 - interleukins 572, 603
 - International Committee of Harmonization (ICH) 720
 - international landscape 514
 - International Organization for Standardization (ISO) 426, 514, 680
 - International Pharmaceuticals Regulatory Forum (IPRF) 516
 - intestinal wall, 386, 579
 - structure of 580
 - intra-articular injections 615
 - intracellular bio-nano interface, nature of 74
 - intracellular delivery 453, 698
 - drug delivery 736
 - intracellular products 303
 - intralesional injection 608
 - intraliposome precipitation 613
 - intramuscular injection 616, 704
 - intratracheal instillation 430, 457
 - intravenously injectable nanoemulsion
 - liposomes, process technology configuration of 325
 - intravenously injectable nanoparticles using top-down process, process technology configuration of 324
 - intrinsic properties 271, 277
 - inventions protection, via patents 678
 - investigational nanomedicines 253
 - in vitro in vivo correlation (IVIVC) 10, 720
 - in vivo experimental animal models, 618
 - evidence from 619–624
 - in vivo topical toxicity tests 431
 - iodine-labeled CNTs 452
 - IPRF. *see* International Pharmaceuticals Regulatory Forum
 - iPSCs. *see* induced pluripotent stem cells (iPSCs)
 - iRGD peptides 449
 - iridium nanoparticles 429
 - irinotecan 699, 702
 - liposome injection 702
 - iron-based preparations 511
 - accumulation 512
 - definition, particles 511
 - nanosized colloidal intravenous 511
 - overarching principle 511
 - pharmacological effects 512
 - toxicological effects 512
 - trafficking 512
 - treatment, iron-deficiency anemia 511
 - iron–carbohydrate complexes 513
 - iron nanoparticles 431, 504
 - iron oxide 3, 54, 543
 - nanoparticles 53, 54
 - irreproducible preclinical research
 - bottleneck for translation 673–678
 - economic costs 675
 - ISCOMs. *see* immune-stimulating complexes (ISCOMs)
 - ISO. *see* International Organization for Standardization
 - isoniazid 634, 640
 - isothermal titration calorimetry (ITC) 719
 - isotropic etching 361
 - ITC. *see* isothermal titration calorimetry (ITC)
- k**
- KADYCLA® 704
 - Kaposi sarcoma 54, 413, 474, 700
 - keratoconjunctivitis sicca 633
 - kinesin spindle protein (KSP) 82
 - Kupfer cells 106, 427, 700
- l**
- lab-on-a-chip systems (LOC) 357
 - laboratory-based prototyping 374
 - laboratory-scale process, study context of 309
 - lactate dehydrogenase leakage 429
 - lactide 254
 - lactide-*co*-glycolides 296
 - LAL assay. *see* limulus amoebocyte lysate (LAL) assay
 - laminated object manufacturing (LOM) 365

- lanthanide-doped upconverting luminescent nanoparticles (UCNPs) 284
- lanthanides 271
- laser fabrication 366
- laser light scattering 709
- laser micromachining 359
- LC. *see* liquid chromatography (LC)
- LCST. *see* lower critical solution temperature (LCST)
- LCT. *see* long chain triglycerides (LCT)
- legal aspects 335
 - Announcement on Hazardous Substances 527 335
 - German Ordinance on Hazardous Substances (GefStoffV) 335
 - laboratory guidelines “Working Safely in Laboratories,” 335
 - NIOSH publications 335
 - REACH legislation 335
 - regulation in the United States, based on ToSCA of 1976 335
- lentiviruses 48
- leukocytes 471
- Lewis lung carcinoma (LLC) cells 254, 255, 458
- LHRH. *see* luteinizing hormone-releasing hormone (LHRH)
- ligand-mediated interaction 51
- ligand–receptor-based targeting 417–418
 - drug in lipid nanoparticles, targeting 420–421
- ligands 18
- limulus amoebocyte lysate (LAL)
 - assay 145, 146, 720
 - test 720
- Limulus polyphemus* 720
- lipid-based formulations 3
- lipid-based nanocarriers 32, 112
- lipid-based nanoparticles 350, 427, 633, 638, 737
 - oxidative stress pathways, activation of 427
- lipid bilayers 167
- lipid emulsions
 - flowchart 299
 - manufacturing of 298
- lipid matrix nanocarriers 112
- lipid nanocapsules 112, 115
- lipid nanoparticles 3, 32, 112, 135, 366, 370, 388, 420, 587, 638, 717
- lipid nanovesicles 114
- lipid particles 103, 371, 407, 414
- lipid vesicles 407, 413
- LipoNasal® 633
- LipoNit® 633
- lipophilic drugs 118
- lipophilic stabilizer 296
- lipophilic substances, direct incorporation 185
- lipophilic surfactants 116
- lipopolysaccharides (LPS) 145
- lipoproteins 29
- liposomal anticancer agents 474
- liposomal cotherapy 115
- liposomal creams 730
- liposomal doxorubicin 409
- liposomal encapsulated drug 470
- liposomal formulations 502, 503
 - bilayer properties 511
 - characterization of physical state 510
 - as delivery system 505
 - medicinal products 505
 - on reflection paper 505
 - state of play 504
- liposomal GCs formulation strategies 612–615
- liposomal medicinal products, 505
 - nonexhaustive list of 506
 - with orphan designation 508
- liposomal membrane 53
- liposomal steroids
 - cytokines secretion, effect on 623
 - tissue pathology 623
- liposomes 4, 23, 26, 45, 48, 50, 53, 103, 114, 181, 295, 297, 303, 413, 456, 535
 - Bangham method, flowchart 300
 - based drugs 46
 - bilayer membrane 609
 - biodistribution 545
 - colloidal lipid structures 185
 - composition 181
 - consist of phospholipids 32
 - DepotFoam® Technology 187
 - derived virosomes 642
 - direct injection method 300
 - – flowchart 301
 - direct loading method, flowchart of manufacturing using 301
 - drug incorporation 185
 - drying of dispersions 188
 - encapsulated drug doxorubicin 413
 - forming lipid 613
 - half-life of 545
 - lipidic bilayer 612
 - liposomal dispersions, preparation 183

- manufacturing of 299
 - nanosterically stabilized
 - anticancer and antifungal drugs 609
 - dynamics and structure of 610
 - liposome-forming lipids 613
 - medical application 610
 - method of preparation 609
 - methods for, encapsulating drugs 610
 - passive loading 610–611
 - remote (active) loading 611–612
 - permeability 610
 - phases 610
 - strategies for, formulating liposomal GCs 612–615
 - surface stabilization of 609
 - treatment of diseases with inflammatory component 609–610
 - versatility in 609
 - physicochemical properties of 416
 - preparation
 - lipid film method 639
 - sterilization 188
 - synthesis 114
 - vesicle distribution, produced by Bangham and direct inject methods 313
 - liquid chromatography (LC) 88, 141, 144, 147
 - liquid drug carrier formulations, processing 176
 - colloidal lipid emulsions 176
 - liposomes 181
 - polymeric nanoparticles 189
 - Liquidia PRINT platform 731
 - lithography 359
 - localized plasmon resonance (LSPR) 275
 - local lymph node assay 431
 - long chain triglycerides (LCT) 638
 - long-term exposure to GCs
 - physiological effects 608
 - lower critical solution temperature (LCST) 239
 - low generation dendrimers
 - kidney, effect on 427
 - low-molecular-weight contrast agents 54
 - low-pressure chemical vapor deposition (LP CVD) 363
 - low-pressure nanonization systems 369–372
 - LPS. *see* lipopolysaccharides (LPS)
 - luminescence 271
 - luminescence nanoparticles
 - schematic representation of, in vivo optical imaging 540
 - Lumirem® 34
 - lupus 603
 - luteinizing hormone-releasing hormone (LHRH) 241
 - lymphatic drainage 45
 - dynamic visualization of 540
 - lymph node imaging 550
 - lymph nodes 471
 - lymphocyte T cell 603
 - LYNPARZA™ 731
 - lyophilization process 206, 718
 - lyophilized powder 703
 - L-lysine 455
 - lysolipids 53
 - lysosomes 69
- m**
- macroinitiators 260
 - macrolactones, structures 258
 - macromolecular drugs 121, 242
 - macromolecules 32, 122, 232, 247, 475, 550, 606, 715, 716
 - macrophage imaging, advantage of 549
 - macrophages 6, 25, 27, 54, 388, 414, 416, 418, 447, 457, 471, 545, 553, 603, 606, 618, 700
 - in blood 416
 - in tissues 416
 - Macugen® 637
 - maghemite (Fe₂O₃) 279, 431
 - magic bullet 3, 522, 525, 605, 697
 - concept 605
 - magnetic drug targeting (MDT) 34
 - magnetic hyperthermia 567
 - magnetic iron oxide nanoparticles 568–571
 - magnetic iron oxide nanoparticles 568–571
 - physical properties of 568
 - toxic effects 568
 - magnetic nanoparticles 279, 568
 - Brownian relaxation time 569
 - hybrid magnetic nanosystem for delivery 280
 - magnetization rotation 569
 - relaxation time of 569
 - stabilization/protection 280
 - synthesis 279
 - thermal dissipation process 569
 - for tumor hyperthermia 570
 - magnetic resonance imaging (MRI), 54, 279, 350, 448, 536, 543, 544, 568, 634, 650
 - clinical contrast agents 543
 - contrast-enhanced imaging 543
 - particles designed for 543
 - signal enhancement in kidney 544
 - signal-to-noise ratio for 543
 - magnetism 271

- major histocompatibility complexes, MHC-I and II 6
- MALS. *see* multiangle light scattering (MALS)
- mammalian cell culture 136
- manganese 55
- manufacturability 715
- marketed nanoparticle products, 725, 730
 - nanocarrier delivery technologies, comparison of 725
- marketed products 212
 - containing API nanoparticles 213
 - Emend® 215
 - Rapamune® 214
- Marketing Authorization Application 500
- Marqibo® 90, 702
- Marqibo™ 82
- M&As. *see* mergers and acquisitions (M&As)
- Massachusetts Institute of Technology (MIT) 365
- mass spectrometry 86, 148
- mass spectroscopy (MS)-based proteomic analysis 87
- material properties 66, 67
 - approach to characterization 70
 - – epitope and recognition motif mapping 71
 - – forces, dynamics, and other processes at bio-nano interface 71–74
 - – nature of early-stage biological recognition 70, 71
 - timescales of Biological Interaction 67
 - – degradation of surface 68, 69
 - – early times 67, 68
 - – long timescales 69
 - – priorities 70
- matrix metalloproteinases 52
- matrix systems 108
- maximum tolerated dose 119, 483, 706
- MCT. *see* middle chain triglycerides (MCT)
- MDR1 gene 489
- measurement of properties 63
- Megace ES® 31, 107
- melamine 427
- membrane-active sterols 610
- MEMS (micro electromechanical systems) sensor 73
- mergers and acquisitions (M&As) 675
- mesoporous silica NPs (MSNs) 279, 282
- mesoporous silica particles 20, 282
- metabolome 86
- metabolomics 81, 88
- metal-based nanoparticles 3, 427, 446
 - used in nanomedicine 446
- metallic coating material 363
- metallic nanomaterials
 - oxidative stress, role in 427
- metal oxide 271
- metal oxide nanomaterials 431
 - aluminum oxide 283
 - calcium phosphate 283
 - hydroxyapatite 283
 - lanthanide complexes 284
 - phototoxicity 431
 - quantum dots (QDs) 284
 - silica/silicon 282, 283
 - silver (Ag) NPs 284
 - titanium oxide 283
- metaphors 525
- metastases diagnosis 536
- methane molecule in a molecular cage 334
- methotrexate (MTX) 52, 241, 618
- methylprednisolone 607
- methylprednisolone acetate 607
- micelles 53, 103, 234
- micelle structure, destabilization of 52
- mice models for inflammatory diseases
- micro- and nano-tools 357, 359
- microbeam radiation therapy (MRT) 168, 475
- microbubbles 540
- microchannel homogenizers 639
- microdevices 359
- microelectrical discharge machining (μEDM) 359, 365, 366
- microenvironments 20, 358, 473, 500, 685, 736
- microfabrication 360
- microfluidic devices 357, 358, 717
- microfluidics technology 304
- microfluidization technology 303, 304, 320
- microfluidizer 180, 181, 203
- microstructure design 361
- micro-tool in preclinical phase of drug discovery 375
- micro-X-ray absorption spectroscopy 160
- middle chain triglycerides (MCT) 638
- military metaphors 526
- mill designs 307
- milling process 195, 198, 199, 298, 307, 339, 564
- miniaturized total analysis systems (μEAS) 357
- Mircera® 33
- MLV. *see* multilamellar vesicles (MLV)
- MM-302 liposomal nanoscale carrier encapsulating doxorubicin (DOX) 83

- MO/DC function 485
- molecular modeling, in nanomedicine 381–384
- monoarthritis 608
- monoclonal antibodies (mAb) 90, 651
- monoclonal IgG antibodies 5
- monomethyl auristan E (MMAE) 4
- mononuclear phagocyte system (MPS) 45, 91, 92, 232, 414, 427, 470–472
 - phenotypic probe of 492
- Morbus Crohn 23
- mouse
 - thermal image, injection of 571
- MPS. *see* mononuclear phagocyte system (MPS)
- MRI. *see* magnetic resonance imaging (MRI)
- MRL-lpr/lpr mice 623
- MRT. *see* microbeam radiation therapy (MRT)
- MS-derived protein patterns 87
- MTX. *see* methotrexate (MTX)
- mucosal barriers 233
- mucus 29
- mucus-penetrating vesicles 32
- multiangle light scattering (MALS) 138, 313
- multidisciplinary 44
- multidrug resistance genes 698
- multifunctional liposomes targeting 656
- multifunctional nanodrugs 49, 51, 53
- multi-inlet vortex mixer 717
- multilamellar vesicles (MLV) 183, 309
- multiple myeloma 90, 506, 700
- multiple sclerosis 54, 381, 549, 604
- multiwalled carbon nanotubes 342, 652
- murine tumors 239
- mushroom configuration 432
- mutagenesis 48
- MWCNT, scanning electron microscope images of 451
- myelosuppression 3, 427
- myocardial inflammation 549
- Myocet® 702
- n**
- nab® technology 33
- nanoamorphous 296, 298, 307, 321, 327
- nanoamorphous suspension, flowchart of manufacturing 296
- Nanobiotix 502
- nanocarrier NK105, 82
- nanocarriers (NCs) 3, 23, 26, 35, 36, 103, 656, 735
 - acute toxicity 713
 - – complement activation 713
 - – hemolysis 713
 - – impaired mitochondrial function 713
 - – inflammation 713
 - – oxidative stress 713
 - based drug delivery, advantages 606
 - biodistribution 714
 - characterization
 - – lack of reliable techniques 737–738
 - classification 103
 - – inorganic 104
 - – organic 104
 - dendrimers 656
 - for drug delivery 103
 - immune system, effects on 720
 - liposomes 656
 - nanoassembly 656
 - pharmacokinetics and biodistribution 736
 - scaling up challenge 738–740
 - stability measurement
 - – lack of reliable techniques 737–738
- nanocrescents 104
- nanocrystalline suspension 296, 308, 320, 323
 - flowchart of manufacturing 296
 - principle of manufacturing of 297
 - using direct comminution, manufacturing of 297
- nanocrystalline suspension using top-down process, process technology configuration for manufacturing of 323
- unit is composed of 323
- nanocrystallization 108
- nanocrystals 3, 31, 275, 282, 295, 582, 651, 717, 725
- NanoCrystal® technology 9, 31
- nanodiamonds 450
- nanodrug delivery systems 295, 296
 - downstream processing of 302
 - as marketed products 302
 - presentation of major manufacturing processes 296
 - sterilization, decision tree of 322
 - value chains for the production of 321
- nanodrugs 51–54, 680
 - routes of administration 634–638
 - – nasal route 635–636
 - – ophthalmic route 636–637
 - – pulmonary route 634–635
 - – vaccination 637–638
- Nanoedge™ technology 108
- nanoelectronics 663
- nanoeulsions 295, 379, 587, 639
- nanoeustrusion 212

- nanoformulation 3, 143, 280, 357, 367, 407, 709, 712, 718, 720, 730
 - clinical application 407
 - in pharmaceutical industry 409
 - pharmacologic effects 412
 - role in, drug development 412
- nanographene 565
- nanohybrids 726
- nanoliposomes 603, 613, 737
 - drug 612
- nanomaterials 17, 331, 333, 342, 565, 575, 652, 665, 680, 683
 - based drug delivery 18
 - risks of, researchers and workers 336
 - – categories with regard to toxic properties 337, 338
- nanomedical translation, regulatory guidance gap 682
- nanomedicine development, guidances issued by regulatory authorities 721
- nanomedicine, nanoparticle biocompatibility uses 443
 - biological-based nanoparticles 456–458
 - carbon-based nanoparticles 450–453
 - clinical applications 447
 - defined 444
 - metal-based nanoparticles 446–448
 - nanoparticles, biocompatibility of 445, 446
 - polymer-based NPs (PNPs) 453–456
 - targeting metal NPs 448–450
 - theranostics 444
- nanomedicines 10, 17, 90, 103, 135, 176, 231, 525, 663, 680
 - administered via inhalation routes
 - – safety assessment 430
 - Agency's reflection on 500
 - applications of nanotechnology 502
 - commercialization, summary of challenges 729–730
 - companies, number of 731
 - convergence on 514
 - definition 499, 500, 535, 663
 - future of 76, 77
 - ICH guidelines 719
 - level of complexity 504
 - mechanisms of action 503
 - pharmaceutical, device and biotechnology industries, influence on 663
 - pharmacokinetic–pharmacodynamic (PK–PD) relationship 713
 - rationale for use of polymers 232
 - scientific evaluation of 503
 - surface coating of 504
 - targeting 63
 - types of 503
 - working description of 503, 515
- nanomedicines commercialization 722–731
 - challenges and initial solutions 726–730
 - key players 730–731
 - nanomedicine market 724–726
 - nanotechnology investment 723–724
- nanomedicines development 705–720, 722
 - into clinical use, improving translation of 706–708
 - – support from specialist groups 708
 - – traditional research and development, lessons learnt from 706–708
 - development process 705–706
 - preclinical development 709–720
 - – analytical considerations 719
 - – formulation and process optimization 714–718
 - – lessons learnt from NCL 719–720
 - – in vitro preclinical development testing 709–712
 - – in vivo preclinical development 712–714
 - regulatory considerations 720–722
- nanomedicines products 407
 - application of pharmaceuticals 407
 - delivery objectives 408
 - drug-carrier particles 407
 - examples of 407
- nanomedicine toxicity 446
- nanomedicine translation, barriers to 669–672
- nanomilling 31, 581
- nano-objects 295, 325, 332, 333, 335, 339, 344, 350, 524, 536
 - forms of 333
- nanoparticle 332, 543, 544, 546, 547
- nanoparticle albumin-bound (nabTM) technology 5
- nanoparticle-based approach 52
- nanoparticle-based drug delivery systems (DDS) 3, 605
 - nasal diseases 640
 - ophthalmic diseases 640–641
 - pulmonary diseases 640
 - targeted disease 640–641
 - vaccination 640–641
- nanoparticle-based drug systems 469
- nanoparticle-based formulation development, challenges 641–642
- nanoparticle biodistribution 4, 44, 68, 544
- nanoparticle capacity 70

- nanoparticle carrier, toxicity 427
- nanoparticle corona 28, 68
- nanoparticle formulations 469, 470, 709
- nanoparticle pulmonary toxicity 430
- nanoparticles (NPs) 43, 63, 64, 144, 271, 296, 332, 469, 649
 - actively using the host machinery 5–8
 - adsorption of proteins 545
 - biodistribution 544–545
 - cadmium–selenium nanoparticle 537
 - challenge 537
 - characterization in biological environment 144
 - clearance 545
 - clinical perspectives of 536
 - components of 547
 - conception of 536
 - contrast-enhanced ultrasound imaging 542
 - cutaneous toxicity 431–432
 - examples of multimodal 548
 - first class 538
 - general distribution of 547
 - gold 545
 - hybrid gadolinium oxide 545
 - immunotoxicity 432–434
 - industrial applications 425
 - – benefits 425
 - integrity of 547
 - interaction with blood constituents 545
 - intrinsic stability 547
 - lactosylated albumin 545
 - liquid-to-gas transition 541
 - list of marketed product based on 303
 - liver prior and post injection of microbubbles 542
 - macrophage imaging by uptake 548
 - for medical imaging 548
 - for optical imaging 536
 - particles designed for, ultrasound imaging 540
 - phagocytosis of 548
 - polymer coating of 454
 - pulmonary toxicity 428–431
 - quantum confinement effect 537
 - second window for, in vivo imaging 541
 - signal-to-noise ratio 537
 - stability 547
 - surface effects 546
 - systemic toxicity 427–428
 - targeting abilities 536
 - zeta potential 111
- nanoparticles actively, using host machinery 5–8
- nanoparticles-based drug delivery systems (DDS) 605–607
- nanoparticles in development
 - nanocarrier delivery technologies, comparison of 726
- nanoparticles manufacturing processes 638–639
 - bottom-up processes 638–639
 - top-down processes 638–639
- nanoparticles regulation
 - Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) 426
- nanoparticle tracking analysis (NTA) 139, 149, 709
- nanoparticle uptake, by immune cells 471
- nanoparticulate formulations 23, 25, 176
- nanopatent filings 679
- nanopatent land grabs 679
- nanopatents 679
- nanopharmacmy, lipid-based- and protein-based 82
- nanopharmaceutical classification system (NCS) 35
- nanopharmaceutical medicines 523
- nanopharmaceutical research, good translation in 523
- nanopharmaceuticals 3–5, 11, 17, 23–25, 29, 31, 34, 35, 43, 56, 175, 212, 430, 523, 581, 661, 680
 - for cancer therapy 45
 - in cancer therapy 4, 5
 - fields of application for 20
 - first generation of 45
 - and optional modifications 31
 - for oral administration and long-acting injectable therapy 8–9
 - regulation of 18
 - safety of 34, 35
 - technical realization of 30
- nanopharmacy (NP) 19, 43–45, 82, 231, 380, 680, 699, 735
 - aim of 36
 - ballistic metaphors 526
 - culture of promise 522
 - drug delivery via magic bullet 522
 - ethical issues of 522
 - horizon of knowledge 522
 - metaphors and 525–526
 - military metaphors 526
 - objects of 522
 - personalized medicine 526
 - social complexity of 524
 - social studies of nanopharmacy 524

- nanopolymeric suspension 296, 299
 - flowchart of manufacturing 296
- nanoprecipitation 33, 110
- nanoprisms 104
- Nanopure® process 202
- nanopyramids 104
- nanoresearch521, 529
 - culture of promise in 523
 - social implications of 521
- nanorods 104, 106, 273, 276, 561, 563
- nanosafety 35, 459
- nanoscale 65
- nanoscale drug delivery system 45, 680
 - platforms 664
- nanoscale structures 164, 332
- nanoscale therapeutics 680
- nanosimilar medicinal products 504
- nanosized APIs 31
- nanosized drug delivery systems 45
- nanosized iron-based colloidal product 513
- nanosized particulate contaminants 435
- nanosomes 469, 474
- nanospheres 104, 189, 562
- nanosterically stabilized liposomes (NSSL) 609
 - fabrication stage of 614
 - pharmacokinetics and biodistribution advantages 619–622
 - transmembrane calcium acetate gradient-driven remote loading
 - – principles and mechanism 614
 - in vivo experimental animal models 618
- nanostructured lipid carriers (NLC) 32, 112, 588
- nanosuspensions 9, 193, 195, 203, 208, 211, 301, 585
 - conversion, into solid intermediate for downstream processing into final drug product 301
- nanosystems 201, 271, 277, 285, 295, 351, 501, 517, 535
- nanotechnological application 331
- nanotechnology 17, 65, 214, 331, 335, 379, 409, 426, 458
 - based formulations 425
- nanotechnology characterization laboratory (NCL) 136, 708
- nanotherapeutics 4, 10, 12, 664, 666, 680, 683
 - stabilization of 10
- NanoTherm® 5, 34, 53, 502
- NanoTherm therapy, 570
 - treatment of prostate cancer 570
- nanotomography 158, 160
- nanotoxicity 35, 95
- nanotoxicology 19, 384, 713, 728
- nasal route for vaccination 633
- nasal spray formulations 635
- National Cancer Institute (NCI) 723
 - evaluated the efficacy of CD19 CARs on patients 85
- National Institute for Occupational Safety and Health (NIOSH) 335, 342, 665
- National Institutes of Health (NIH) 666
- National Nanotechnology Initiative 723
 - define nanotechnology 331
- “natural” scale 65
- NBCDs. *see* nonbiological complex drugs (NBCDs)
- NCE. *see* New Chemical Entity (NCE)
- NCL. *see* National Cancer Institute (NCI)
- NCL. *see* Nanotechnology Characterization Laboratory (NCL)
- NCs. *see* nanocarriers (NCs)
- nearfield light scattering (NLS) 74
- Néel relaxation 568
- neodymium oxide particles 427
- Neoral® 587
- Neulasta® 33, 704
- neuraminidase 637
- neuritic plaques 649
- neurotoxic substances 25, 27
- neutron beams, complementary 157
- neutron reflection 167
- neutron reflectometry 167
- neutron sources 157
- neutropenia 3
- neutrophils 427, 451, 481, 484, 603, 606
- New Chemical Entity (NCE) 676, 713
- new medicines driver 697–699
- new molecular entities (NMEs) 675
- next generation sequencing (NGS) 82, 86
 - based studies 87
- N-(2-hydroxypropyl)methacrylamide (HPMA) 241
- NIH. *see* National Institutes of Health (NIH)
- NIOSH. *see* National Institute for Occupational Safety and Health (NIOSH)
- NIR-II optical probes 540
- nitric oxide (NO) 603, 653
- NK cell functions 457
 - cytotoxic activity 457
- NLC. *see* nanostructured lipid carriers (NLC)

- NM. *see* nanomaterial
 NMDA receptor antagonist 653
 NMDA receptor-mediated neurotoxicity 653
 NMEs. *see* new molecular entities (NMEs)
 NMR. *see* nuclear magnetic resonance spectroscopy (NMR)
 nonbiological complex drugs (NBCDs) 721
 noncellular barriers 27
 nongenomic pathways 607
 nonionic surfactants 111, 177, 609
 nonporous and mesoporous metal oxide NPs 283
 nonpredictive animal models 737
 nonsmall cell lung cancer (NSCLC) 238
 nonsolvent 296
 nonstabilized liposomal agents 472
 nontransferring-bound iron (NTBI) 514
 nonviral delivery vesicles 48
 nonviral gene therapy 49
 nonviral vectors 48
 Novantrone® 737
 novel biomaterials 698, 716
 novel chemistries 698
 novel delivery modes 500
 Noyes–Whitney equation 8
 NPs. *see* nanoparticles (NPs)
 NSCLC. *see* nonsmall cell lung cancer (NSCLC)
 NSSL. *see* nanosterically stabilized liposomes (NSSL)
 NTA. *see* nanoparticle tracking analysis (NTA)
 nuclear magnetic resonance spectroscopy (NMR) 143, 146, 381
 nucleic acids 48
 – based drugs, protein production, effect on 697
 – based therapeutics, immunogenicity 435
 – delivery 705
 – drugs 720
 – therapy 48
 Nude/SCID/Rag mice 737
 NWCNT. *see* multiwalled carbon nanotubes
- o**
- occupational health and safety 332, 335, 339, 351, 352
 OECD. *see* Organization for Economic Cooperation and Development (OECD)
 OELs (occupational exposure limits) 336
 oil-in-water nanoemulsion 640
 oligonucleotides 5, 8, 87, 232, 242, 276, 656, 697
 omics technologies 93
 Oncaspar® 33, 681
 oncogene (Bcl2L12) 84, 477
 Oncorine 48
 Onivy® 702
 Opaxio® 4, 47, 238
 ophthalmic drug delivery 27
 ophthalmic route 633, 636
 opsonins 92, 236, 471, 545, 548, 618
 optical access 359
 optical capacitors 539
 optimal process conditions 297
 oral drug delivery 8, 20, 23, 167, 579, 581, 585, 588
 – availability of, broad spectrum 579
 – bioavailability of drugs 580, 586
 – biopharmaceutical drawback 580
 – branched nanocarriers 585
 – challenges of 579
 – dendrimers 585
 – general aspects 579
 – nanoemulsions 587
 – nanotechnology platforms for 581
 – permeability through membranes 580
 – polymeric micelles 585
 – polymeric nanoparticles 590–591
 – pure drug nanoparticles 581, 585
 – solid lipid nanoparticles (SLNs) 587–590
 organic nanocarriers 32, 104, 124
 organic nanostructures 106, 123
 – for drug delivery 104
 organic solvent 32, 46, 109, 110, 113–115, 120, 122, 144, 183, 188, 192, 203, 204, 256, 296, 297, 300, 309, 311, 639, 738
 organic solvent-free synthesis 114, 115
 Organization for Economic Cooperation and Development (OECD) 342, 426, 514
 – document 342
 organ-on-a-chip (OOC) 357, 358, 372–375
 ortho-nitrobenzyl (ONB) 277
 osmotic distillation 314, 325
 – schematic of 315
 Ostwald–Freundlich equation 8
 Ostwald ripening 195, 202–204, 297
- p**
- PACA. *see* poly(alkyl cyanoacrylates) (PACA)
 paclitaxel (PTX) 5, 23, 33, 45–47, 90, 92, 192, 216, 234, 238, 247, 248, 277, 407, 409, 453, 455, 456, 488, 586, 699, 703, 725
 – loaded nanocarriers, 92
 – – targeted or untargeted 92
 pair-distribution function (PDF) 158, 163
 palmar-plantar erythrodysesthesia (PPE) 409, 428, 482, 485, 701
 pancreas cancer 702

- paramagnetic temperature-responsive liposomes 55
- parenteral nutrition 176, 177, 638
 - emulsions for 177
- particle replication in nonwetting templates (PRINT) technology 478, 684, 717
 - highly fluorinated perfluoropolyether elastomer, use of 718
 - polymeric nanoparticles preparation 718
- particle size 20, 63, 297, 298
 - particle size and size distributions (PDI) 717
 - reduction techniques 8, 9, 319
 - vesicle size reduction technologies 302
- particulate contaminants 178, 429, 434, 435
- parvoviruses 8
- passive loading 610, 613
 - definition 610
 - encapsulation efficiency 611
 - packing parameter principles 611
- paste formation and hydration 310
- PAT. *see* process analytical technologies (PAT)
- patent holder 679
- patent infringement 679
- patent prospectors 679
- patent situation 678
- patient-derived xenografts (PDXs) 737
- PBSu. *see* poly(butylene succinate) (PBSu)
- PCL. *see* poly(ϵ -caprolactone) (PCL)
- PCR. *see* polymerase chain reaction (PCR)
- PCS. *see* photon correlation spectroscopy (PCS)
- PDF. *see* pair-distribution function (PDF)
- PDLLA. *see* poly(DL-lactic acid) (PDLLA)
- PDMS (polydimethylsiloxane) material 359, 360, 364
- PDXs. *see* patient-derived xenografts (PDXs)
- peak of inflated expectations 680
- PEG. *see* polyethylene glycol (PEG)
- pegaptanib 637
- Pegasys® 704
- PEG-DSPE. *see* polyethyleneglycol-coupled distearylphosphatidylethanolamine (PEG-DSPE)
- PEG-modified liposomal doxorubicin (PEGL-DOX) 482
- PEG-PEI-cholesterol lipopolymer 49
- PEG-PLA. *see* polyethylene glycol-polylactic acid (PEG-PLA)
- PEGylated AuNPs 447
- PEGylated liposomal cisplatin (SPI-077) 474
- PEGylated liposomal CKD-602 (S-CKD602) 474, 480–484, 487–489
- PEGylated liposomal doxorubicin (PLD) 46, 473, 475, 476, 486
 - monocyte subpopulations 482–483
- PEGylated liposomes 46, 54, 92, 427, 472, 473, 479, 484, 491
 - drug formulations 483
 - in tumors 473
- PEGylated poly(L-histidine) copolymer 52
- PEGylated proteins 4, 44, 67, 122, 233, 242, 243, 699, 703, 704
 - preparation 243
 - properties 242
- PEGylation reagents 243
- PEI. *see* poly(ethyleneimine) (PEI)
- PEI–DNA complexes 49
- pelletization 210, 212
- penicillin G 63, 76, 118
- peptides 5, 22, 30, 33, 34, 43, 48, 50, 88, 91, 147, 241, 242, 276, 280, 412, 415, 448, 473, 579, 591, 655, 737
- peripheral human tumors 606
- persistent luminescence nanoparticles 539, 540, 546
- personalized medicine 12, 36, 55, 82, 88, 92, 285, 526–528, 536, 723
- personalized oncology, using nanomedicine 90
 - passive tissue targeting *vs.* active cellular targeting 90–92
 - RNA interference (RNAi), approach for Cancer Personalized Therapy 92, 93
- personal omics profiling 88–89
- PET. *see* positron emission tomography (PET)
- PGA. *see* poly(glycolide) (PGA)
- p*-glycoproteins 655
- Pgp inhibitors 489
- phagocytosis 106, 387, 394, 415, 429, 445, 450, 451, 471, 483–485, 548
 - by alveolar macrophages 429
 - CNT-induced toxicity 451
 - by macrophages 445
 - in MO/DC 483, 484
- phagosomes 68, 69
- pharmaceutical database 725
- pharmaceutical design 581, 706
- pharmaceutical formulations, unintended presence of nanosized materials 434–435
- pharmaceutical industry 199, 307, 336, 351, 409, 456, 515, 522, 605, 727, 729
- pharmaceutical nanocarriers, suitable and common size for 18–19, 191
- pharmaceutical products 34, 36, 176, 234, 306, 434, 580, 581
- pharmacodynamics (PD) 146, 379, 396, 405, 470, 522, 607, 642, 663

- anticancer CMAs 470
- of CMAs 470
- effect of MPS 480–483
- future perspectives 491, 492
- pharmacokinetics (PK) 17, 35, 44, 53, 54, 379, 470
 - characterization 470
 - of CMAs 470
 - effect of MPS 480–483
 - future perspectives 491, 492
 - liposomal encapsulated drug 470
 - parameters 510
- pharmacological research 523, 528
- pharma-oriented nanoparticle 159
- phase II clinical trial 237, 419, 549
- PhenoGLO–high-throughput screening platform (HTSP) 482
- philosophical reflection 524
- pH-induced release 21, 22
- phospholipase A2, 52
- phospholipidic bilayer
 - membranes 45
 - schematic presentation of 2000-PEG-DSPE incorporated in 617
- phosphorylcholine methacrylates 243
- photodynamic therapy (PDT) 22, 185, 449, 565, 572, 575
 - reactive oxygen species (ROS) 565
 - TiO₂ nanoparticles 565–567
 - tumor-localizing photosensitizer (PS) 565
 - upconversion nanoparticles (UCN) 567
- photolithography 359
- photoluminescence phenomenon 539
- photon correlation spectroscopy (PCS) 138
- photosensitive release 22
- photothermal therapy 105, 561
 - in vivo near-infrared (NIR) laser 563
- pH-sensitive components 52
- physical vapor deposition (PVD) 363
- physicochemical characterization 36, 137, 145, 149, 575, 634, 640, 710
- physiologically based pharmacokinetic models (PBPK) 389–391
 - examples of models 391–394
 - future perspective of modeling 394, 395
 - integration of experimental data in models 391
 - limitations of approach 394
- physiopathological mechanisms 535
- piecemeal development 727
- pin stirred mill 320
 - bead mill 307, 308
- piston gap technologies 303, 304, 306, 319, 320
- pittsburgh compound-B (PiB) 650
- PLA. *see* poly(lactic acid) (PLA)
- planetary mill 320, 321
- plasma-activated bonding 363
- plasma coagulation time 434
- plasma-enhanced chemical vapor deposition (PE CVD) 362, 363
- Plasmodium berghei*, 618
- platelets 106, 471
 - derived growth factor 603
- plate-shaped material containing nanotubes integrated in 334
- plate-shaped nano-objects 332, 333
- platinum-based anticancer drug 447
- PLD post-chemotherapy cycle 490
- PLLA. *see* poly(L-lactic acid) (PLLA)
- Pluronic F108, 453
- poly-ADP-ribose polymerase (PARP) 84
- poly(alkyl cyanoacrylates) (PACA) 109
- polyamidoamine 427, 545
- poly(amidoamine) (PAMAM)
 - dendrimers 585
- poly(anhydrides) 253
- polyarthritis 608
- poly(butylene succinate) (PBSu) 254
- poly(caprolactone) (PCL) 189, 253
- polycondensation reactions 190, 251
 - Fischer esterification 251
 - mechanisms 251
 - transesterification 251
- poly(DL-lactic acid) (PDLA) 256
- poly-ε-caprolactone (PCL) 33, 109, 253, 456
- polyelectrolyte complexes 231
- polyelectrolyte material 277
- polyethylene glycol (PEG) 45, 47, 67, 110, 142, 202, 427, 447, 456, 473, 545, 586, 617, 737
 - coating, of AuNPs 449
 - protein conjugates 242
- polyethylene glycol-b-poly(lactico-glycolic acid) (PEG-b-PLGA) nanoparticles 717
- polyethylene glycol–polylactic acid (PEG–PLA) 650
- polyethylene glycolylated (PEG) 447
- polyethyleneglycol-coupled distearylphosphatidylethanolamine (PEG-DSPE) 181
 - 2000-PEG-DSPE, phospholipidic bilayer, incorporation in 617
- poly(ethyleneimine) (PEI) 49, 241
- poly(glycolide) (PGA) 254
- polyglycolides 296
- poly(N-(2-hydroxypropyl) methacrylamide) (HPMA) 455

- poly(lactic acid) (PLA) 109, 167
 - PLA-HPG-Ad 477
- poly(lactide-co ϵ -caprolactone)-d-
 α -tocopheryl polyethylene glycol 1000
 succinate (PLA-PCL-TPGS) NPs 456
- polylactides 296
- poly(L-glutamic acid) 47
- poly(L-lactic acid) (PLLA) 256
- polymerase chain reaction (PCR) 652
- polymer-based nanocarriers 32
- polymer-based nanoformulations 3
- polymer-based nanomedicines 454
- polymer-based nanoparticles (PNPs) 23, 453, 641
 - L-lysine functionalization 455
- polymer degradation 249
- polymer–drug conjugates 232, 240
- polymeric matrix nanocarriers 108
- polymeric micelles 33, 52, 141, 231, 233, 585
 - formation 585
 - hydrophobic blocks 586
 - oral bioavailability 586
 - physical instability of 586
- polymeric nanoparticles 48, 189, 295, 590–591
 - Abraxane® 192
- polymeric nanosuspension 321, 325
- polymeric nanovesicles 112
- polymer matrix 117, 119
- polymer nanomedicines 238, 248, 261
- polymers 48, 231
 - as active drug ingredient 231
 - advances synthesis for therapeutic applications 248
 - as carriers for drug molecules 379
 - conjugation to drugs 240
 - conjugation to proteins 240
 - morphology 234
 - noncovalent or covalent conjugation of 379
 - properties 234
 - structures 234
- polymersomes 112, 114, 116, 118, 122, 234, 240
- polyoxazolines 243
- polyoxyethylated castor oil 703
- poly(ϵ -caprolactone) (PCL) 109
- poly(ethylene glycol) (PEG) 231, 455
- poly(lactic-co-glycolic acid) (PLGA) 453
- polysorbate 80 29, 177, 180
- poly(trimethylene carbonate) (PTMC) 253
- polyvalent 241, 333
- pore size 20, 179, 180, 183, 184, 282, 283, 395, 476, 606
- porous silicon NPs (pSi) 283
- positron emission tomography (PET) 650
- postsurgery healing 603
- PowderJect 25
- PPE. *see* palmar-plantar erythrodysesthesia (PPE)
- precision medicine 82, 633
- precision oncology 83
- preclinical biomedical research 666, 668
- preclinical development, key in vitro tests required 710–712
- preclinical investigation 48, 372
- preclinical reproducibility 675
 - steps to improve 676
- preclinical reproducibility rates
 - investing in practical solutions to improve 676
- prednisolone phosphate 613, 616
- pressure evolution within the valve 306
- PRINT PLGA nanoparticles 481
- PRINT technology. *see* particle replication in nonwetting templates (PRINT) technology
- pristine nanoparticles 137
 - physicochemical characterization 137
 - – batch particle sizing techniques 138
 - – separation- and fractionation-based sizing techniques 140
 - – single particle sizing techniques 139
 - – size distribution 137
 - – topology 137
- process analytical technologies (PAT) 716
- process development 184, 189, 200, 210, 308
 - scale-down/scale-up strategy 308
- prodrugs 135, 609, 613
- product clearance 678
- product contamination 193, 196, 199, 200, 202
- product development pathway 667
- Products Quality Research Institute (IPQRI) 504
- ProHance® 55
- proinflammatory cytokines 572, 623
- prophylactic therapy 697
- prostate-specific membrane antigen (PSMA) 51, 85
- protective measures 344–351
 - guidelines assign, to nanomaterials for orientation purposes 349
 - measures for avoiding unwanted contamination 349, 350
 - nanomaterials in healthcare, categories as per Announcement on Hazardous Substances 527 350
 - nanotechnologies, generations types 351
 - order 344

- range of simple questions allow a check 344, 345, 348, 349
- work procedures 344
- protein-based biomarkers 87
- protein-based nanoparticles 33
- protein corona 142, 146
- protein–drug conjugate nanoparticles 3
- protein recognition 5
- proteins 5, 17, 28, 29, 33, 34, 66
- proteome 86
- prudent practices, and proven concepts for controlling risks 338
- risk assessment 338–341
- – exposure routes 339
- – flowchart 340
- – oral exposure 341
- workplace measurements 341–343
- Pseudomonas aeruginosa*, 419, 633
- Pseudomonas* exotoxin (PE) 419
- Pt–DNA adducts 474
- PTMC. *see* poly(trimethylene carbonate) (PTMC)
- public health sector, impact of nanotechnology 515
- Public Health Service Act 678
- Pulmaquin® 633
- pulmonary drug delivery system 24, 640
- pulmonary, ophthalmic, nasal, and vaccination routes
- combined selective references 635
- pulmonary route 634
- advantages 634
- vs. peroral route 634
- pulmonary surfactant 29
- pure drug micronization 580–581
- pure drug nanoparticles 581
- mucoadhesiveness 581
- for oral administration 582–584
- oral bioavailability 581
- production 581
- saturation solubility 581
- pyrosequencing technology 87

q

- QDs. *see* quantum dot (QDs)
- quality-adjusted life expectancy years 722
- quality by design 716
- quantum confinement effect 537
- quantum dot (QDs) 103, 284, 537, 546, 651, 665
- clinical applications 537
- cytotoxicity 537

- degradation 537
- diameter of 537
- metabolism 537
- quartz crystal microbalance (QCM) 71, 73, 149
- binding curves related to recognition of receptors on cell surface in flow by 73
- sensor 72, 73
- Quillaja brasiliensis*, 637
- Quillaja saponaria* Molina, 637

r

- rabbit ocular toxicity 431
- radioisotope labeling 148
- radiotherapy 169, 571
- RAFT polymerization. *see* reversible addition fragmentation chain transfer (RAFT)
- polymerization
- Rapamune® 31, 107, 214, 215, 303, 408, 582
- rat hepatocyte couplets (RHC) 454
- RCC. *see* Regulatory Cooperation Council (RCC)
- REACH. *see* Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH)
- reactive oxygen species (ROS) 282, 428, 429, 482, 483, 565, 571, 651
- receptor ligands 5
- receptor-mediated transcytosis (RMT) 477
- receptor molecules 366
- recombinant immunotoxin molecules 420
- recombinant proteins 303
- recycling number 320
- redox-responsive nanodrugs 52
- redox-responsive polymers 240
- reduce cell–particle interactions 455
- reduction–oxidation reaction 363
- reflection paper (RP) 11, 503, 504, 510, 721
- parameters for, iron-based colloidal product 513
- principles for 511
- time-dependent measurement of, iron content 513
- use 511
- Registration, Evaluation, Authorization, and Restriction of Chemicals (REACH) 426
- legislation 335
- Regulatory Cooperation Council (RCC) 426
- remote (active) loading 611–612
- agent's level of ionization 611
- principles and mechanism of NSSL transmembrane 614
- stages 611

- RES. *see* reticuloendothelial system (RES)
- research and development process. 705
- resonant mass measurement instrument setup 73
- respiratory distress syndrome 633
- responsive nanodrugs 50, 51
- resveratrol 589, 653–655
- reticuloendothelial system (RES) 28, 29, 110, 232, 233, 449, 513, 617
- retro-Michael reaction 245
- retroviruses 48
- reversible addition fragmentation chain transfer (RAFT) polymerization 259, 260
- rheumatoid arthritis 7, 12, 272, 604
- Rienso® 34
- rifampicin 118, 586, 589, 634
- right culture 708
- right efficacy 707
- right exposure 707
- right to use 678
- ring-opening polymerization 251
- anionic 252
 - cationic 252
 - coordination–insertion 252
- RISC–RNA complex 92
- ritonavir 587
- rivastigmine 653, 655
- RNAi-based therapeutics 731
- RNAi-induced gene silencing 92
- RNA-induced silencing complex (RISC) 92
- RNA interference (RNAi) 8, 47, 92
- RNA molecules 49
- ROS. *see* reactive oxygen species (ROS)
- routes of administration
- different types of nanoparticles 638
- 5 R's 707
- right commercial potential 707
 - right patient 707
 - right safety 707
 - right target 707
 - right tissue 707
- S**
- safety 444, 454
- safety classification system for nanoproducts and materials based on their “nonnano” forms 36
- safety of nanoproducts 35
- safety testing 35
- Sandimmune® 587
- SANS. *see* small angle neutron scattering (SANS)
- saquinavir 587
- SAXS. *see* small-angle X-ray scattering (SAXS)
- scale-down/scale-up strategy 308
- scale-up and scale-down strategies 318
- scaling up of vesicle size reduction technique 316
- scattering 43, 139, 159, 167, 271, 275, 719
- SCFs. *see* supercritical fluids (SCFs)
- science and technology studies (STS) 521
- science facilities 170
- science meets society 523
- scientific culture 673
- S-CKD602, 474
- in male/female rats 487
 - pharmacokinetic disposition 488
 - pharmacokinetic disposition of 488
- secondary intermolecular interactions 716
- electrostatic interactions 716
 - hydrogen bonding 716
 - hydrophobic–hydrophobic interactions 716
 - stereocomplexation 716
- secondary ion mass spectrometry (SIMS) 143
- secreted protein acid and rich cysteine (SPARC) 5, 248
- selenium 537
- self-emulsifying drug delivery systems (SEDDSs) 587, 588
- semiconductors 64, 66, 271, 284, 537
- sensationalism 44
- sepsis 162, 603
- serine proteases 603
- SET-LRP. *see* single-electron transfer-living radical polymerization (SET-LRP)
- shock waves 305
- short hairpin RNA (shRNA) 92
- silencing RNA (siRNA)
- conjugated to Au NPs for gene regulation 276
- silica 34
- silica nanoparticles 103
- silicon 359
- anisotropic etching of 361
- silicon direct bonding (SDB) 363
- silicon nitride (Si_3N_4) 307, 362, 363
- silicon oxide (SiO_2) film 361, 362
- silver nanoparticles (AgNPs) 103, 284, 392, 393, 665
- SIMS. *see* secondary ion mass spectrometry (SIMS)
- simulation of nanoparticle
- pharmacokinetics 386
 - nanoparticle absorption 386–388
 - nanoparticle distribution 388, 389
 - nanoparticle elimination 389

- simulation, of processes 380
- single-cell sequencing 89
- single-electron transfer-living radical polymerization (SET-LRP) 260
- single particle inductively coupled plasma mass spectrometry (sp-ICP-MS) 140
- single-wall carbon nanotubes (SWCNTs) 333, 451, 564
- siRNA. *see* small interfering RNA (siRNA)
- siRNA-loaded SNA (siL12-2-SNA) 477
- sirtuin pathway 655
- size and shape 65
- size reduction 307
- Sjögren's syndrome 608
- skin 566
- SKOV-3 flank xenografts 478
- SKOV-3 ovarian 474
- SLN. *see* solid lipid nanoparticles (SLN)
- SL printer, schematic buildup of 365
- SLS. *see* static light scattering (SLS)
- small-angle neutron scattering 144, 167
- small angle neutron scattering (SANS) 144, 160, 167
- small-angle X-ray scattering (SAXS) 144, 158, 160, 164, 165, 738
- small interfering RNA (siRNA) 92, 165
 - coating 477
- small-molecule drugs 699
- small- to medium-size enterprises (SMEs) 727
- SMCC. *see* succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC)
- SMEs. *see* small- to medium-size enterprises (SMEs)
- soft lithography 359, 360, 478
- solid lipid nanoparticles (SLN) 3, 32, 112, 297, 298, 587–590, 633
 - colloidal systems 587
 - encapsulation capacity of 587
 - limitation of 588
 - and NLCs for, improvement of oral pharmacokinetics of drugs 588–590
 - physicochemical stability 587
 - stability in stomach 588
- SOLiD sequencing 87
- solubility 4, 8, 17, 19, 20, 31, 90, 212, 239, 337, 456, 586, 612, 636, 699, 709, 711
- solubility barrier 20
- solvent displacement method 120, 190
- solvent removal
 - after dispersion sizing 314
 - after emulsification 314
 - during freeze-drying step 312
 - kinetic and vesicle size change using osmotic distillation 316
- sonodynamic therapy (SDT) 572
 - anticancer treatment 572
 - mechanism of ROS generation 573
 - in vivo fluorescent imaging of tumor site 573
- SOPs. *see* standard operating procedures (SOPs)
- SPARC. *see* secreted protein acid and rich in cysteine (SPARC)
- SPDP. *see* N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP)
- spearment 256
- spherical nucleic acids (SNAs)
 - nanoparticle 477
- sphingomyelin 115
- sp-ICP-MS. *see* single particle inductively coupled plasma mass spectrometry (sp-ICP-MS)
- SPIO. *see* superparamagnetic iron oxide (SPIO)
- SPR. *see* surface plasmon resonance (SPR)
- spray-coating 210, 211, 215
- spray-drying 8, 183, 185, 191, 204, 206–210, 301, 302
- spray-freeze drying 107, 111, 297
- sputtered thin metal films 363
- stabilizer 297
- standardization 64, 374, 514, 680, 708, 722
- standard operating procedures (SOPs) 708
- Staphylococcus aureus*, 616
- starch 33, 211
- static light scattering (SLS) 138
- STEALTH® liposomes 32
- stereolithography (SL) 365
- sterically stabilized liposomes (SSL) 617
- sterility 137, 145, 175, 188
- stimuli-responsive nanodrugs 52
- stimuli-responsive release 21
- stirred bead milling 306
- stirred media milling 194
- stock market 663
- storage stability 32
- stroke 43, 54, 640
- structure-activity relationships 431, 433
- subsequent film hydration 114
- succinimidyl iodoacetate (SIA) 121
- succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) 121
- N-succinimidyl-3-(2-pyridyldithio)-propionate (SPDP) 121
- sunscreens and cosmetics
 - nanomaterials, based on cutaneous toxicity 431
- superconductors 64

- supercritical fluids (SCFs) 108, 115, 584
 - superparamagnetic iron oxide (SPIO) 34, 650
 - superparamagnetic iron oxide nanoparticles (SPION) 5, 33, 279, 568
 - advantages of 34
 - commercially available 34
 - surface adsorption 146
 - surface character 65
 - surface chemistry 271
 - surface energy 366, 718
 - surface engineering technologies 366
 - surface-enhanced laser-desorption ionization time-of-flight MS (SELDI-TOF-MS) 88
 - surface-enhanced Raman scattering (SERS)-based sandwich assay 652
 - surface functionalization 366
 - surface plasmon resonance (SPR) 43, 105, 146, 561, 719
 - schematic illustration 562
 - wavelength shifts 43
 - surface plasmons 135
 - surface-to-size ratio 544
 - surfactant-based nanoformulations 3
 - surfactants 118
 - Span 118
 - Tween 118
 - suspensions 175, 191, 202, 209, 303, 306
 - sustained release 21
 - SWCNT surfaces 452
 - synchrotron light 157
 - schematic of 161
 - synchrotron micro-X-ray fluorescence 160
 - synchrotron radiation 157
 - synthetic cationic liposomes 48
 - synthetic nonviral vector systems 48
 - synthetic plasmid design 239
 - synthetic polyesters 253
 - in development 254
 - of glycolide 254
 - as investigational nanomedicines 253
 - of lactide 254
 - poly(anhydrides) 253
 - poly(caprolactone) 253
 - poly(trimethylene carbonate) 253
 - Systems Approach to Drug Targeting 405
 - biological context 406
 - biomedical research 407
 - drug delivery 405–407
 - drug formulation 406
 - graphical representation of 405
 - guidance and specification 406
 - physiological context 406
 - rate-limiting steps 406
- t**
- tamoxifen 277
 - target brain tumors 475–477
 - targeted nanodrugs 50
 - ideal design of 50
 - targeted nanoparticles 550
 - targeting 29
 - active 30
 - passive 30
 - tau protein 652, 655
 - taurine-functionalized CNTs 452
 - TBD. *see* 1,5,7-triazabicyclo[4.4.0]dec-5-ene (TBD)
 - T-cell 7, 85, 457, 619, 623, 655
 - TCR–CD3 complex interaction 85
 - TEARS AGAIN® 633
 - technological concept for manufacture of drug product for human use (GMP Unit) 322
 - tellurium 537
 - TEM. *see* transmission electron microscopy (TEM)
 - temperature 358, 363
 - template nanoparticle 54
 - temporal resolution 166
 - theranostic, nanodrugs 54
 - advantage 55
 - therapeutic activity 51, 707
 - therapeutic agents 48, 605
 - therapeutic efficacy 18, 43, 605
 - of nanodrugs 49
 - therapeutic gene cassette 48
 - therapeutic index 34, 605, 697
 - therapeutic interventions 43
 - therapeutic mAbs 83, 84
 - therapeutic molecule 54
 - therapeutic monoclonal antibodies (mAbs) 83
 - therapeutic product, 11, 216, 410
 - clinical research 411
 - discovery of gene 410
 - pharmaceutical drug discovery and development 411
 - therapeutic treatment/vaccine 410
 - translational research 411
 - treatment/vaccine 410
 - therapeutic proteins, immunogenicity 242, 243, 245, 418, 435
 - therapeutic small-molecules inhibitors 84, 85
 - therapeutic submarkets 36
 - therapies 3
 - thermal ablation 34, 53, 453
 - thermal bonding 363
 - thermoablation 570
 - ThermoDox® 4, 53

- thermoluminescence 539
- thermoreponsive release 22
- thin film deposition 359, 362, 363
- thiol alkylation 245
- third generation of NPs 271
- three-dimensional printing technologies 364
- three-dimensional reconstruction, of
 - immunogold label positions 72
- tiered approach for determining the situation
 - regarding exposure by inhalation 343
- TiO₂ nanoparticles 565–567
 - bandgap energy 566
 - biocompatibility 565
 - optical absorption of 566
 - photocatalytic activity 565
 - phototoxic effect of 566
 - potential photosensitizing agent 565
 - practical applications 566
 - schematic illustration of, photodynamic reaction 566
 - toxicity 565
- tissue pathology 623–624
- T-lymphocyte repertoires 457
- TM. *see* translational medicine (TM)
- TMC. *see* trimethylene carbonate (TMC)
- TME. *see* tumor microenvironment (TME)
- TONIC. *see* Translation of Nanotechnology in Cancer (TONIC)
- top-down processes 298
 - comminution 297
 - – process flowchart of 298
 - high-pressure homogenization 639
 - rotor–stator mechanism 639
 - sonication 639
- total internal reflection microscopy (TIRM) 74
- toxicity 3, 10, 34, 35, 110, 147, 271, 373, 385, 405, 427, 431, 435, 447, 455, 492, 713, 715, 735
- toxicity related to nanotherapeutics 10
- toxicological assays 35, 36
- toxicological evaluation 34
- Toxic Substances Control Act (TSCA) 426
- TPP. *see* tripolyphosphate (TPP)
- traditional drug therapy, limitations associated with 3
- transcriptomes 86, 89
- transcriptomic 88
- transdermal drug delivery 25
- trans epithelial electrical resistance (TEER) 374
 - measurement 375
- transesterification 251
- transferrin protein (Tf) 66, 72
 - protein 477
- transition temperature 53
- translating nanotechnology 63
- translation, 11, 37, 47, 92, 149, 434, 458, 523, 666, 678, 708, 713, 731, 735
 - clinical trials 524
 - complications 524
 - nanopharmaceutical medicines 523
 - nanopharmaceutical process of 524
 - notion of 524
 - research development 524
 - as social process 523
- translational medicine (TM) 667, 683, 684, 691
- translational nanomedicine 682, 683, 686
 - improvement in lab to clinic 684–686
- Translation of Nanotechnology in Cancer (TONIC) 728
- transmission electron microscopy (TEM) 139, 709, 719
- trastuzumab emtansine 4
- triamcinolone acetonide 637
- 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) 256
- triblock copolymers 234, 235
- Tricor® 31, 107
- Triglide® 31
- trimethylene carbonate (TMC) 253
- tripolyphosphate (TPP) 111
- Trojan horses 20
- trough of disillusionment 680
- TRPS. *see* tunable resistive pulse sensing (TRPS)
- TSCA. *see* Toxic Substances Control Act (TSCA)
- tumor 4, 5, 30, 47, 52, 82, 90, 95, 168, 283, 413, 418, 449, 472–474, 478, 542, 565, 571, 701, 736, 740
 - measurement 563
 - treatment of, solid and large tumors 567
 - in vivo fluorescent imaging of 573
 - in vivo obliteration of, solid malignant 564
- tumor-associated antigens 85, 418
- tumor-associated macrophages 54
- tumor exposure 472, 474, 478
- tumor heterogeneity 87, 95, 736
- tumor microenvironment (TME) 247, 473, 491, 736

tumor necrosis factor- α 603
 tumor shrinking effect 740
 tumor-specific antigens 418
 tumor type
 – NC's delivery mode of action (MoA)
 matching 736–737
 tumor vascular architecture 542
 tumor vasculature 30, 53, 90, 473, 542
 tunable resistive pulse sensing (TRPS) 139, 142

u

UCNPs-based delivery systems 284
 UCST. *see* upper critical solution temperature (UCST)
 ultrafine aerosols 331, 332, 338, 340
 ultrasmall silicate nanoparticles 544, 547
 ultrasmall SPIONs magnetite (Fe_3O_4) 279
 ultrasound 21, 25, 27, 52, 115, 536, 542, 572
 uncertainty management 336
 unencapsulated drug 510
 United States Food and Drug Administration (US-FDA) 256
 upconversion nanoparticles (UCNPs) 538, 546, 567
 upper critical solution temperature (UCST) 239
 ureas 5
 US-FDA. *see* United States Food and Drug Administration (US-FDA)
 US Federal Food, Drug, and Cosmetic Act 676
 US Food and Drug Administration (FDA) 3, 32, 46, 54, 147, 420, 426, 581, 636, 650, 673, 677, 686, 700, 702, 710, 721, 735, 737, 739
 US National Nanotechnology Initiative (NNI) 681

v

vaccines 7, 23, 25, 32, 177, 256, 415, 416, 633–638, 641
 – delivery 23
 – nanotechnology 5
 validation 10, 323, 385, 386, 396, 410, 575, 676
 valley of death in commercialization 668
 van der Waals interactions 610
 vascular drug therapy 635
 vascular endothelial growth factor (VEGF) 82, 93, 489, 637
 vascular permeability 46, 51, 607, 618, 736
 vascular system
 – dynamic visualization of 540
 vascular thrombosis 106
 vasculature permeability measurement 549

vector–nucleic acid complex 49
 VEGF. *see* vascular endothelial growth factor (VEGF)

Verteporfin 185, 186, 506

vesicle size, 298, 302, 308, 311, 313, 316–319, 322

– distribution of liposomes, characteristic diameters
 – as function of residual ethanol content in dispersion before freeze-drying 317
 – obtained using Bangham and direct injection techniques 316
 – of final product, impact of process on 316
 vesicle size reduction 302, 303, 308, 311, 312, 317, 319
 – as function of ethanol content in dispersion 311
 – kinetic obtained at two different scales 317
 – kinetic of Bangham and direct injection methods, comparison of 312
 – kinetics obtained in batches using HPH 318

vesicular systems 112, 702

vincristine 90, 182, 187, 434, 508, 702

viral infections 89, 636, 640

viral nanoparticles 48, 474

virosomes 3, 6, 635, 641

volcanic ash 34

vomiting 3, 215

w

water-soluble drugs 46, 115, 119, 212, 587

water-soluble fullerene derivatives

– kidney, effect on 427

water-soluble matrix 365

waveguide (WG) 74, 75

WAXS. *see* wide-angle X-ray scattering (WAXS)

wet chemical 360

– and dry etching 360

WHO. *see* World Health Organization (WHO)

whole-exome technologies (WES) 86, 87, 89

whole genome sequencing (WGS) 86–89

wide-angle X-ray scattering (WAXS) 144, 165, 738

Working Party on Manufactured Nanomaterials (WPMN) 426

workplace measurements 341–343

World Health Organization (WHO) 345, 499, 665, 669, 700

WPMN. *see* Working Party on Manufactured Nanomaterials (WPMN)

x

Xenograft human breast tumors
92

XPS. *see* X-ray photoelectron spectroscopy
(XPS)

X-ray fluorescence 158

X-ray photoelectron spectroscopy (XPS)
143

y

yttrium-stabilized zirconium oxide 195

z

Zinc-doped-SPIONs 280

zirconium oxide 307

zirconium silicate 307

zymosan-induced inflammation 618, 621